Last €75.81 EUR
Change Today +0.11 / 0.15%
Volume 1.6M
SAN On Other Exchanges
Symbol
Exchange
EN Paris
EN Paris
New York
OTC US
BrsaItaliana
Mexico
Frankfurt
Frankfurt
NASDAQ GM
As of 11:35 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Karen Linehan

Executive Vice President of Legal Affairs and General Counsel, Sanofi
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 2 different industries.

55--

Background*

Ms. Karen Linehan has been General Counsel at Sanofi since March 2007 and serves as its Executive Vice President of Legal Affairs. Ms. Linehan serves as General Counsel at Sanofi-Aventis S.A. (Spain). She served as a Senior Vice President of Legal Affairs at Sanofi. In January 1991, Ms. Linehan joined Sanofi as Assistant General Counsel of its US subsidiary. In July 1996, she moved to Paris to work on international matters within the Group and she has held a number of ...

Read Full Background

Corporate Headquarters*

54, Rue La Boétie
Paris, Ile-de-France 75008

France

Phone: 33 1 53 77 40 00
Fax: --

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

JD
Georgetown University
BA
Georgetown University

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAN:FP €75.81 EUR +0.11

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
John C. Martin Ph.D.Chairman and Chief Executive Officer
Gilead Sciences Inc.
$1.6M
Marijn E. Dekkers Ph.D.Chairman of Management Board and Chief Executive Officer
Bayer AG
€2.9M
Andrew Philip Witty Chief Executive Officer, Executive Director, Member of Corporate Administration & Transactions Committee and Member of Finance Committee
GlaxoSmithKline plc
2.9M GBP
Kenneth C. Frazier Chairman and Chief Executive Officer
Merck & Co. Inc.
$1.5M
Lars Rebien Sørensen Chief Executive Officer
Novo Nordisk A/S
kr15.2M
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.